A4S: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation

被引：9
|
作者：
Germani, Massimiliano [1 ]
Del Bene, Francesca [1 ]
Rocchetti, Maurizio [1 ]
Van Der Graaf, Piet H. [2 ]
机构：
[1] Accelera Srl, Pharmacokinet & Modeling, I-20014 Nerviano, MI, Italy
[2] Pfizer Ltd, Pharmacometr, Global Clin Pharmacol, Sandwich CT13 9NJ, Kent, England
来源：
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE | 2013年 / 110卷 / 02期
关键词：
Pharmacokinetic and pharmacodynamic; Compartmental analysis; Tumor Growth Inhibition model; Matlab; Model based drug development; NONMEM; DECISION-MAKING; DRUG DISCOVERY; MODEL; INTEGRATION; KINETICS; PROGRAM; MATLAB; IMPACT; GUIDE; PHASE;
D O I：
10.1016/j.cmpb.2012.10.006
中图分类号：
TP39 [计算机的应用];
学科分类号：
081203 ; 0835 ;
摘要：
Effective communication of PK/PD principles and results in a biomedical research environment remains a significant challenge which can result in lack of buy-in and engagement from scientists outside the modeling and simulation communities. In our view, one of the barriers in this area is a lack of user-friendly tools which allow "non experts" to use PK/PD models without the need to develop technical skills and expertise in advanced mathematical principles and specialist software. The costs of commercial software may also prevent large-scale distribution. One attempt to address this issue internally in our research organizations has resulted in the development of the A4S ("Accelera for Sandwich") software, which is a simple-to-use, menu-drive Matlab-based PK/PD simulator targeted at biomedical researchers with little PK/PD experience. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：203 / 214
页数：12
相关论文
共 50 条
  • [31] Pharmacodynamic-pharmacokinetic (PD/PK) profile of the phosphodiesterase (PDE)4 inhibitor, V11294A, in human volunteers.
    Gale, DD
    Landells, LJ
    Spina, D
    Miller, AJ
    Smith, K
    Nichols, T
    Rotshteyn, Y
    Tonelli, F
    Lacouture, P
    Burch, RM
    Page, CP
    O'Conner, BJ
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A108 - A108
  • [32] Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of serdemeten-induced QTc effects in a first-in-human study
    Huntjens, D. R.
    Van Beijsterveldt, L.
    Kraljevic, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of PRO132365, a HER2 antibody-drug conjugate
    Tibbitts, J.
    Jumbe, N.
    Liepold, D.
    Dugger, D.
    Crocker, L.
    Sliwkowski, M. X.
    Fielder, P. J.
    Kenkare-Mitra, S.
    EJC SUPPLEMENTS, 2006, 4 (12): : 65 - 65
  • [34] Development of a pharmacokinetic/pharmacodynamic (PK/PD)-simulation system for doxorubicin in long circulating liposomes in mice using peritoneal P388
    Tsuchihashi, M
    Harashima, H
    Kiwada, H
    JOURNAL OF CONTROLLED RELEASE, 1999, 61 (1-2) : 9 - 19
  • [35] Pharmacokinetic(PK)/pharmacodynamic(PD) evaluation of CHF 2819.01 (novel cholinesterase inhibitor) in patients with probable Alzheimer's disease.
    Jhee, SS
    Fabbri, L
    Zarotsky, V
    Piccinno, A
    Rosenthal, M
    Moran, SV
    Ereshefsky, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P66 - P66
  • [36] Translational Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling Strategy to Support RG6042 Dose Selection in Huntington's Disease (HD)
    Ducray, Patricia Sanwald
    Frances, Nicolas
    Smart, Kevin
    Norris, Dan
    Kordasiewicz, Holly
    Guenther, Andreas
    Wild, Edward
    Schobel, Scott
    NEUROLOGY, 2019, 92 (15)
  • [37] Impact of population pharmacokinetic (PK) modeling, logistic regression and PK/pharmacodynamic (PD) simulation of solabeoron to aid in the dose selection of a phase IIB study in patients with irritable dowel syndrome (IBS).
    Cox, Donna S.
    Boyle, Duane A.
    Foss, Michael J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1101 - 1101
  • [38] Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Escherichia coli
    Jitaree, Kamonchanok
    Sathirakul, Korbtham
    Houngsaitong, Jantana
    Asuphon, Orarik
    Saelim, Weerayuth
    Thamlikitkul, Visanu
    Montakantikul, Preecha
    ANTIBIOTICS-BASEL, 2019, 8 (03):
  • [39] Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation
    Asuphon, O.
    Montakantikul, P.
    Houngsaitong, J.
    Kiratisin, P.
    Sonthisombat, P.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 50 : 23 - 29
  • [40] Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.
    Simonelli, M.
    Zucali, P. A.
    De Sanctis, R.
    Lorenzi, E.
    De Vincenzo, F.
    Rimassa, L.
    Tronconi, M. C.
    Personeni, N.
    Masci, G.
    Zuradelli, M.
    Perrino, M.
    Bertossi, M.
    Giordano, L.
    Santoro, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345